Two things to note on Ultraleap - IP took a huge write down at the mid year last year (-26.5mn from 31mn for a carrying value of 4.5mn ) and it appears that Ultraleap cleared all of its registered charges in November last year. |
I think you are somewhat jumping the gun in two cases there. Istesso hasn't been written down to zero and the debt breach sounded historic prior to the recent sales. |
Ultra leap, breached the debt covenant, IPO will be well down the pecking order when they turn off the lights. To join Istesso in the 100% write off pot. |
News on Ibex Innovations - IP Group 35.9% |
News on ULTRALEAP - IP Group 20.4%
Not sure if this means a little cash is salvaged from this situation or not. |
Date of purchase: 18/03/2025
Number of ordinary shares purchased: 74,692
Volume weighted average price paid per ordinary share (GBp): 42.9599
08:22:22-12:17:12
===============
The rise in share price is likely still capping the buyback. |
TR-1
Lombard Odier Asset Management (Europe) Limited
Position of previous notification 9.97% [reverse dilution[?] takes holding to 96,155,772 or 10.05%]
Plus CFD 0.92%
Total 104,894,450 or 10.97% |
 FOR RELEASE ON
18 March 2025
IP Group - Notice of results and Investor Presentation
IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, announces that it intends to publish its results for the year ended 31 December 2024 on Tuesday 25 March 2025.
The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the Investor Relations section of the company's website at www.ipgroupplc.com.
Key members of IP Group plc's leadership team will provide a live presentation via the Investor Meet Company platform on 25 March 2025 at 10am.
Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: Investors who already follow IP Group on the Investor Meet Company platform will automatically be invited. |
Date of purchase: 17/03/2025
Number of ordinary shares purchased: 119,127
Volume weighted average price paid per ordinary share (GBp): 42.1109
08:11:10-12:45:56 |
Further experiments suggest at least another 2 for AT LEAST 3/14 of the total in a year. It highlights the importance. More than 3 = VERY IMPORTANT.
As they have exceeded the pressure record I think it will be top priority to see where it reaches before rolling over. 100% increase in 12 months is massive, there might be more to be achieved.
This is valuable. |
They allocate only around 14 shots per year and the fact FLF have more due within 12 months highlights the importance - you don't waste shots when there are so few to use.
FLF have doubled pressure in around a year.
They had a test, data collect, simulate many, modify, re-test approach.
"Proposals undergo a competitive review process involving non-Sandia referees, with the facility typically awarding about 14 shots per year. [First Light has further experiments at Sandia planned over the next 12 months.]" |
First Light Fusion Sets A New Record For The Highest Pressure Recorded On Sandia’s Z-Machine
17 Mar 2025
First Light’s unique amplifier technology has unlocked record-breaking pressures in quartz on the Z Machine
Sandia National Laboratories[1] is home to the Z Machine, the world’s largest and most powerful pulsed power machine
The successful campaign demonstrates the applicability of First Light’s unique technology on other driver platforms and opens up new research opportunities in fusion, defense and space |
Date of purchase: 14/03/2025
Number of ordinary shares purchased: 43,001
Volume weighted average price paid per ordinary share (GBp): 41.0799
08:19:45-10:38:03 |
They've been busy recently-
11 Mar 2025
Vytal
Vytal Global Secures €14.2 Million Growth Funding to Scale Tech-Driven Reusable Packaging and Cement Global Market Leadership
11 Mar 2025
AccelerComm
AccelerComm® Appoints Satellite Industry Veteran Richard Greco as Chairman to Propel Growth in 5G Non-Terrestrial Network Solutions
05 Mar 2025
Mixergy
Mixergy and Ambion team up their low-carbon technology for sustainable homes
04 Mar 2025
Oxford Nanopore Technologies plc
Oxford Nanopore - Annual results for the year ended 31 December 2024
04 Mar 2025
Mixergy
Mixergy Secures £12 Million in Funding Led by Barclays
03 Mar 2025
First Light Fusion
First Light Fusion Announces Strategic Update
26 Feb 2025
Microbiotica
Microbiotica presented new data on the mechanism of action of MB097, a clinical-stage drug candidate being developed as a co-therapy in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma
24 Feb 2025
Oxford Nanopore Technologies plc
Oxford Nanopore expands compatibility with 10x Genomics to unlock deeper insights in single-cell transcriptomics |
Date of purchase: 13/03/2025
Number of ordinary shares purchased: 400,000
Volume weighted average price paid per ordinary share (GBp): 39.9498
08:24:26-16:13:11 |
Date of purchase: 12/03/2025
Number of ordinary shares purchased: 450,000
Volume weighted average price paid per ordinary share (GBp): 40.3132
08:33:03-16:22:10 |
I'd prefer they pull an ipo rather than do it at a poor price or see a post ipo price collapse. Find out soon. |
Date of purchase: 11/03/2025
Number of ordinary shares purchased: 400,000
Volume weighted average price paid per ordinary share (GBp): 39.7979
08:12:12-16:17:36
Buy back volume could be slightly constrained by price limits/averages over past five sessions.
=========
Additional info, from RNS 18/12/2023 IP Group plc - Share buyback programme
"The maximum price paid per Ordinary Share (exclusive of expenses) will be no more than the higher of: (i) 5 per cent above the average of the middle market quotations taken from the London Stock Exchange Daily Official List for the five business days preceding any Ordinary Shares being purchased; and (ii) the higher of the price of the last independent trade and the highest independent bid for Ordinary Shares on the trading venue where the purchase is carried out."
Also RNS dated 08/01/2025 IP Group plc - Share buyback programme update |
"Stability" is it. |
Assuming the market is stable enough to get the IPO away the valuation might be surprisingly decent.
As a guide people are pointing to the last funding round of Sword Health which was completed @6 months ago at a $3 Billion valuation. These business appear very similar except for the fact that Sword only has about a quarter of Hinge's revenue. |
I think so too but there is a real risk by Summer it's all different. Yesterday may be looked oupon as an important day that leads to what we believe is in the bag to change. |
Yup - it's now just a question of price but per my earlier post (before IPO released their RNS ;-) ) there's a very real chance of good monetisation vs NAV and quickly. |
FORM S-1
REGISTRATION STATEMENT |
FOR RELEASE ON
11 March 2025
IP Group plc - Hinge Health files for IPO
IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, is pleased to note that portfolio company Hinge Health Inc ("Hinge Health" or "the Company") has filed its IPO prospectus with the US Securities and Exchange Commission.
As the founding investor in Hinge Health, IP Group has a 1.8% holding in the Company, valued by IP Group at £34.2m as at 30 June 2024.
Headquartered in San Francisco, California, Hinge Health leverages software, including AI, to largely automate care for joint and muscle health. The company has designed its platform to address a broad spectrum of MSK care - from acute injury, to chronic pain, to post-surgical rehabilitation - and the platform can help to ease members' pain, improve their function, and reduce their need for surgeries, all while driving health equity by allowing members to engage in their exercise therapy sessions from anywhere.
Hinge Health noted that the number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Hinge Health intends to list its Class A common stock on the New York Stock Exchange under the ticker symbol "HNGE."
Morgan Stanley, Barclays and BofA Securities are acting as lead book-running managers for the proposed offering. Evercore ISI, RBC Capital Markets, Truist Securities, Stifel, William Blair, Piper Sandler, Canaccord Genuity, KeyBanc Capital Markets, Needham & Company, Raymond James, and KKR Capital Markets LLC are also acting as book-running managers. |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
